SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Catriona Crossan, Emmanuel A Tsochatzis, Louise Longworth, Kurinchi Gurusamy, Brian Davidson, Manuel Rodríguez-Perálvarez, Konstantinos Mantzoukis, Julia O’Brien, Evangelos Thalassinos, Vassilios Papastergiou, Andrew Burroughs, Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation, Health Technology Assessment, 2015, 19, 9, 1

    CrossRef

  2. 2
    Susanne Tan, Nils Vollmar, Sven Benson, Jan-Peter Sowa, Lars P. Bechmann, Guido Gerken, Dagmar Fuhrer, Ali Canbay, Liver Injury Indicating Fatty Liver but Not Serologic NASH Marker Improves under Metformin Treatment in Polycystic Ovary Syndrome, International Journal of Endocrinology, 2015, 2015, 1

    CrossRef

  3. 3
    Nikolaos K. Gatselis, George Ntaios, Konstantinos Makaritsis, George N. Dalekos, Adiponectin: a key playmaker adipocytokine in non-alcoholic fatty liver disease, Clinical and Experimental Medicine, 2014, 14, 2, 121

    CrossRef

  4. 4
    Iliana Doycheva, Rohit Loomba, Effect of Metformin on Ballooning Degeneration in Nonalcoholic Steatohepatitis (NASH): When to Use Metformin in Nonalcoholic Fatty Liver Disease (NAFLD), Advances in Therapy, 2014, 31, 1, 30

    CrossRef

  5. 5
    Ilkay S. Idilman, Onur Keskin, Atilla Halil Elhan, Ramazan Idilman, Musturay Karcaaltincaba, Impact of sequential proton density fat fraction for quantification of hepatic steatosis in nonalcoholic fatty liver disease, Scandinavian Journal of Gastroenterology, 2014, 49, 5, 617

    CrossRef

  6. 6
    Hala Ahmadieh, Sami T. Azar, Liver disease and diabetes: Association, pathophysiology, and management, Diabetes Research and Clinical Practice, 2014, 104, 1, 53

    CrossRef

  7. 7
    Samir Rouabhia, Natasa Milic, Ludovico Abenavoli, Metformin in the treatment of non-alcoholic fatty liver disease: safety, efficacy and mechanism, Expert Review of Gastroenterology & Hepatology, 2014, 8, 4, 343

    CrossRef

  8. 8
    E. B. Mitchel, J. E. Lavine, Review article: the management of paediatric nonalcoholic fatty liver disease, Alimentary Pharmacology & Therapeutics, 2014, 40, 10
  9. 9
    Laura Pala, Valeria Barbaro, Ilaria Dicembrini, Carlo Maria Rotella, The therapy of insulin resistance in other diseases besides type 2 diabetes, Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity, 2014, 19, 3, 275

    CrossRef

  10. 10
    KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease, Clinical and Molecular Hepatology, 2013, 19, 4, 325

    CrossRef

  11. 11
    Barbara Fruci, Stefania Giuliano, Angela Mazza, Roberta Malaguarnera, Antonino Belfiore, Nonalcoholic Fatty Liver: A Possible New Target for Type 2 Diabetes Prevention and Treatment, International Journal of Molecular Sciences, 2013, 14, 11, 22933

    CrossRef

  12. 12
    Feng Zhang, Desong Kong, Yin Lu, Shizhong Zheng, Peroxisome proliferator-activated receptor-γ as a therapeutic target for hepatic fibrosis: from bench to bedside, Cellular and Molecular Life Sciences, 2013, 70, 2, 259

    CrossRef

  13. 13
    Scott S. Malinowski, Jennifer S. Byrd, Allison M. Bell, Marion R. Wofford, Daniel M. Riche, Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease in Adults, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2013, 33, 2
  14. 14
    G. Musso, M. Cassader, F. Rosina, R. Gambino, Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials, Diabetologia, 2012, 55, 4, 885

    CrossRef

  15. 15
    Thuy-Anh Le, Rohit Loomba, Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis, Journal of Clinical and Experimental Hepatology, 2012, 2, 2, 156

    CrossRef

  16. 16
    Suzanne E. Mahady, Jacob George, Management of Nonalcoholic Steatohepatitis, Clinics in Liver Disease, 2012, 16, 3, 631

    CrossRef

  17. You have free access to this content17
    E. Boettcher, G. Csako, F. Pucino, R. Wesley, R. Loomba, Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis, Alimentary Pharmacology & Therapeutics, 2012, 35, 1
  18. 18
    Naga Chalasani, Zobair Younossi, Joel E Lavine, Anna Mae Diehl, Elizabeth M Brunt, Kenneth Cusi, Michael Charlton, Arun J Sanyal, The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association, The American Journal of Gastroenterology, 2012, 107, 6, 811

    CrossRef

  19. 19
    Naga Chalasani, Zobair Younossi, Joel E. Lavine, Anna Mae Diehl, Elizabeth M. Brunt, Kenneth Cusi, Michael Charlton, Arun J. Sanyal, The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology, Gastroenterology, 2012, 142, 7, 1592

    CrossRef

  20. You have free access to this content20
    Naga Chalasani, Zobair Younossi, Joel E. Lavine, Anna Mae Diehl, Elizabeth M. Brunt, Kenneth Cusi, Michael Charlton, Arun J. Sanyal, The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association, Hepatology, 2012, 55, 6
  21. 21
    Angela Mazza, Barbara Fruci, Giorgia Anna Garinis, Stefania Giuliano, Roberta Malaguarnera, Antonino Belfiore, The Role of Metformin in the Management of NAFLD, Experimental Diabetes Research, 2012, 2012, 1

    CrossRef

  22. 22
    Hyohun Park, Toshihide Shima, Kanji Yamaguchi, Hironori Mitsuyoshi, Masahito Minami, Kohichiroh Yasui, Yoshito Itoh, Toshikazu Yoshikawa, Michiaki Fukui, Goji Hasegawa, Naoto Nakamura, Mitsuhiro Ohta, Hiroshi Obayashi, Takeshi Okanoue, Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease, Journal of Gastroenterology, 2011, 46, 1, 101

    CrossRef

  23. 23
    Briohny W. Smith, Leon A. Adams, Non-alcoholic fatty liver disease, Critical Reviews in Clinical Laboratory Sciences, 2011, 48, 3, 97

    CrossRef

  24. 24
    Brian Lam, Zobair M Younossi, Novel treatment strategies for patients with nonalcoholic fatty liver disease, Clinical Investigation, 2011, 1, 2, 229

    CrossRef

  25. 25
    Mariko Hojo, Sumio Watanabe, Pharmacological therapy of nonalcoholic steatohepatitis, Hepatology Research, 2011, 41, 3
  26. 26
    Suzanne E. Mahady, Angela C. Webster, Sarah Walker, Arun Sanyal, Jacob George, The role of thiazolidinediones in non-alcoholic steatohepatitis – A systematic review and meta analysis, Journal of Hepatology, 2011, 55, 6, 1383

    CrossRef

  27. 27
    Giovanni Musso, Roberto Gambino, Maurizio Cassader, Gianfranco Pagano, A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease, Hepatology, 2010, 52, 1
  28. 28
    Marina Núñez, Clinical syndromes and consequences of antiretroviral-related hepatotoxicity, Hepatology, 2010, 52, 3
  29. 29
    M. O. Rakoski, A. G. Singal, M. A. M. Rogers, H. Conjeevaram, Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis, Alimentary Pharmacology & Therapeutics, 2010, 32, 10
  30. 30
    G A Garinis, B Fruci, A Mazza, M De Siena, S Abenavoli, E Gulletta, V Ventura, M Greco, L Abenavoli, A Belfiore, Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study, International Journal of Obesity, 2010, 34, 8, 1255

    CrossRef

  31. 31
    Vlad Ratziu, Stephen Caldwell, Brent A. Neuschwander-Tetri, Therapeutic trials in nonalcoholic steatohepatitis: Insulin sensitizers and related methodological issues, Hepatology, 2010, 52, 6
  32. 32
    Mathias Plauth, Tatjana Schütz, Nutritional Management of Digestive Disorders, 2010,

    CrossRef

  33. 33
    Lance L. Stein, Mamie H. Dong, Rohit Loomba, Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status, Advances in Therapy, 2009, 26, 10, 893

    CrossRef

  34. 34
    Histologic abnormalities of NASH are improved by insulin-sensitizing agents, Nature Clinical Practice Gastroenterology & Hepatology, 2008, 5, 10, 536

    CrossRef

  35. 35
    Mohammad S. Siddiqui, Arun J. Sanyal, Drug Therapy for NASH: Insulin-Sensitizing Agents (Metformin and Thiazolidinediones),
  36. 36
    Stephen H. Caldwell, Curtis K. Argo, Non-Alcoholic Fatty Liver Disease and Nutrition,
  37. 37
    Fernando Bril, Kwame Ntim, Romina Lomonaco, Kenneth Cusi, Treatment of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH),